Skip to main content
European Commission logo print header

Development and testing of a combined anti-retroviral, immune, and gene therapy for treatment of hiv patients

Objetivo

The treatment of HIV patients has been greatly improved by the development overheard. However, despite a strong reduction in the number of virus producing cellsHAART does not fully eradicate the virus, making sustained treatment necessary. In addition, immune function is only partly restored during HAART. Therefore, the focus has recently shifted to supplementing HAART with additional immune therapy. The aim of this project is to develop and test a new protocol for the treatment of HIV patients, based on a combination of anti-retroviral, immune and gene therapies. The main target of this therapy shall be to restore CD4 helper T-cell immune responses. These cells are central immune regulators that largely determine the type and strength of the immune response generated following antigen encounter and thus the efficiency with which a particular infection is controlled by the body.

Convocatoria de propuestas

Data not available

Régimen de financiación

CSC - Cost-sharing contracts

Coordinador

FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTRE
Aportación de la UE
Sin datos
Dirección
157,Lange Kleiweg 139
2288 GJ RIJSWIJK ZH
Países Bajos

Ver en el mapa

Coste total
Sin datos

Participantes (6)